HONG KONG DRUG LICENSING

Hong Kong Drug Licence FAQs

Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.

Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.

Official information from the Drug Office Official information from the Chinese Medicines Board

找到 500 条结果，第 18／25 页。每页显示 20 条；无需启用 JavaScript。

Thematic illustration for pharmaceutical licensing business queries and document organisation services — Discuss actual operating questions one-to-one to clarify the next decision.

Q341 · 在药品批发公司中，质量部门（Quality Unit/Department）的具体角色和职责是什么？独立链接

The quality department is the “guardian” responsible for protecting medicine quality, independent of commercial operations such as sales and procurement. Its core responsibility is to ensure that all company activities strictly comply with GDP requirements and the internal Quality Management System. Specifically, the quality department’s responsibilities span the entire operation: it establishes and maintains QMS documentation (such as SOPs); leads or participates in all key quality-related activities, including deviation investigations, change control, CAPA management and internal and external audits; conducts supplier and customer qualification checks; provides GDP training to staff; reviews and approves all quality-related records; makes final decisions on returns, complaints and recalls; and releases finished products to the market. To fulfil these responsibilities, the quality department must be given sufficient authority and resources, and its decisions must not be influenced by commercial interests.

📘 Regulatory basis

GDP principles emphasise the need for an independent quality system, with its implementation overseen by authorised personnel (usually within the quality department). The RP is generally the head of the quality department and has ultimate responsibility for the effectiveness of the quality system.

📗 Drew Tang's recommendations

We recommend that clients, including small companies, clearly appoint at least one full-time or part-time quality lead and give them clear responsibilities and independence. The quality department should not be seen as the “brakes” on the business, but as its “navigator”. By becoming involved early in the design of new business activities and processes, the quality department can help the company establish a compliant and efficient operating model from the outset.

📕 Risk notice

A quality department with no real authority or no presence at all is one of the most serious organisational deficiencies in the regulator’s eyes. If quality decisions are driven entirely by sales or profit, the entire QMS is a mere formality. If an investigation into a quality incident finds that the department’s independence was compromised, the company and its management will face extremely serious consequences.

Q342 · 当发现运输途中的冷链药品出现了温度偏差（Temperature Excursion），我该如何处理？独立链接

A temperature excursion is an urgent and serious matter that requires an investigation to be initiated immediately. Step 1: Immediately segregate the affected medicines in an “under investigation” area, clearly label them and prohibit their entry into saleable stock. Step 2: Record the excursion details, including the temperature outside the permitted range, its duration and all relevant details of the transport process. Step 3: Contact the medicine manufacturer immediately and provide complete temperature excursion data. Only the manufacturer has the medicine’s stability data and can authoritatively determine whether the excursion has had an unacceptable impact on its quality, safety and efficacy. Step 4: Decide on the final disposition of the medicines based on the manufacturer’s written assessment. If the manufacturer considers that their quality has been compromised, they must be destroyed in accordance with requirements. If the manufacturer provides data demonstrating that the excursion was within acceptable limits, the medicines may be released.

📘 Regulatory basis

GDP requires all deviations during transport to be investigated and recorded. For temperature-sensitive medicines, any temperature deviation must be assessed to ensure that product quality has not been affected before a decision is made on subsequent handling.

📗 Drew Tang's recommendations

Your SOP should include a procedure specifically for handling temperature excursions. Establish communication channels with your main medicine suppliers (manufacturers) in advance and find out whom to contact and what data format is required in the event of a temperature excursion. Do not decide for yourself that an excursion is ‘not serious’. All communications with the manufacturer and its final assessment must be kept on file in writing; these are the sole basis for your decision on how to proceed.

📕 Risk notice

Releasing a batch of medicines that has experienced a temperature excursion without supporting stability data from the manufacturer is an extremely dangerous gamble. You cannot guarantee the efficacy or safety of the medicine. If this is discovered by the regulatory authorities or causes harm to a patient, the consequences will be disastrous. Destroying a questionable batch is a financial loss; selling a problematic batch is a legal and ethical disaster.

Q343 · 为确保库存准确和防止混淆，有哪些库存管理的最佳实践？独立链接

Accurate inventory management is the foundation of GDP, and is key to effective traceability and error prevention. Best practices include: 1. **Clear location management**: Assign a unique code to every shelf, level and location in the warehouse, and link product information to the location code in the system. 2. **Status segregation**: Strictly separate inventory with different statuses, both physically and in the system, such as “released goods”, “quarantined goods pending examination”, “returned goods” and “non-conforming goods / goods pending destruction”, and use clear signs to identify each area. 3. **First in, first out / first expiry, first out (FEFO)**: Your Warehouse Management System (WMS) should support the FEFO principle to ensure that products with the earliest expiry dates are dispatched first. 4. **Cycle counting**: Replace the traditional annual full stocktake with ongoing counts of a small proportion of inventory daily or weekly. This helps identify and correct discrepancies earlier, keeping system data accurate. 5. **Batch-level management**: All inventory operations must be managed at batch level to ensure that the movement of every product batch is recorded accurately.

📘 Regulatory basis

GDP requires inventory records to accurately reflect actual stock, including quantities and batch numbers. It also requires measures to prevent mix-ups and cross-contamination and compliance with the FEFO principle. These requirements place high demands on inventory management accuracy.

📗 Drew Tang's recommendations

We strongly recommend that clients invest in a fully functional barcode-scanning Warehouse Management System (WMS). Requiring product barcodes and location codes to be scanned at every stage, including receipt, put-away, picking, checking and dispatch, can greatly reduce human error and keep inventory data accurate in real time. This is standard equipment for modern pharmaceutical warehousing.

📕 Risk notice

Disorganised inventory management is a breeding ground for dispatching the wrong goods or expired medicines. Inaccurate stock data means your traceability system is unreliable, and you may be unable to locate products quickly in an urgent recall. If inspectors find significant discrepancies between inventory records and actual stock during an inspection, they may consider your entire warehousing operation to be out of control.

Q344 · 用于GDP活动中的计算机化系统（如WMS, ERP）需要满足哪些验证和管理要求？独立链接

Computerised systems used to manage critical GDP activities (such as warehouse management systems (WMS), enterprise resource planning systems (ERP) and temperature and humidity monitoring systems) must themselves be controlled to ensure that the data they generate are reliable, accurate and secure. These systems require Computer System Validation (CSV), with documented evidence demonstrating that they consistently meet their intended functions and regulatory requirements throughout their lifecycle. CSV generally follows the GAMP 5 (A Risk-Based Approach to Compliant GxP Computerized Systems) framework. Key management requirements include: 1. **Data integrity**: the system must be designed to ensure compliance with the ALCOA+ principles; 2. **Audit trail**: the system must automatically record all activities relating to the creation, modification and deletion of GxP data, including timestamps and operator information; 3. **Access controls**: grant users the minimum system access necessary for their roles and responsibilities; 4. **Backup and recovery**: validated procedures must be in place to back up data regularly and restore it reliably when required; 5. **Change control**: any changes to the system (such as software upgrades or configuration changes) must be managed through a formal change control procedure.

📘 Regulatory basis

GDP expressly requires that the suitability of a computerised system be demonstrated before it is used, usually through validation. The system must prevent unauthorised access or modification, provide an audit trail and allow data backup. Annex 11 of the EU GDP guidelines and US FDA 21 CFR Part 11 are generally accepted standards in this area.

📗 Drew Tang's recommendations

When procuring a new system, make “support for GxP compliance” a key selection criterion. Ask the supplier to provide relevant documentation on its software development and testing. For cloud services (SaaS), you need to audit the service provider's quality system and security measures. CSV is a specialist field; if you lack in-house experience, consider seeking external expert support to plan and carry out validation activities.

📕 Risk notice

Using an unproven, “black-box” computer system to manage your pharmaceutical stock and quality data is unacceptable to regulators. If your system lacks an audit trail, you will be unable to explain any changes to the data. An uncontrolled computer system is a major source of risk to data integrity and may be sufficient for the entire quality system to be judged non-compliant.

Q345 · 什么是留存样品（Retention Sample）？药品批发商需要保存吗？独立链接

A retention sample is a representative sample taken and kept from each batch of medicines. Its main purpose is to ensure that, in the event of a product quality complaint, suspected counterfeit medicines or an investigation, an original-condition sample identical to the distributed product is available for examination and testing. Under GMP, medicine manufacturers must retain sufficient samples of every batch released from the factory. Hong Kong GDP regulations do not require pharmaceutical wholesalers to retain samples of all products. However, in certain circumstances—for example, where a wholesaler has carried out an operation that may affect the integrity of product packaging (such as relabelling), or where required under a quality agreement with the manufacturer—the wholesaler may also need to retain samples.

📘 Regulatory basis

The PIC/S GMP Guide sets out clear and detailed requirements for manufacturers to retain samples. Hong Kong's GDP guidelines do not impose the same requirement on wholesalers, placing this responsibility mainly on manufacturers.

📗 Drew Tang's recommendations

Although this is not a statutory requirement, we recommend that wholesalers clearly allocate responsibility for retaining samples and specify how to obtain them in quality agreements with their main suppliers. You need to ensure that, when necessary, you can quickly obtain a retained sample of a particular batch from the manufacturer to support an investigation. For products that you have repackaged, for example, we strongly recommend retaining samples yourself, as you determine the product’s final state.

📕 Risk notice

If neither the manufacturer nor your company has retained a sample when handling a quality complaint, the investigation will be at a serious disadvantage. You will lack the most direct physical evidence for assessing whether the complaint is genuine or identifying the root cause. While this does not in itself constitute a breach by the wholesaler, it will significantly undermine your ability to handle quality incidents.

Q346 · 在设计或改造药品仓库时，有哪些关键的GDP布局要求需要考虑？独立链接

The core design principles for a GDP-compliant warehouse layout are to ensure clear goods flows, prevent mix-ups and cross-contamination, and provide suitable storage conditions. Key layout requirements include: 1. **Functional zoning**: clearly separate, physically or by other effective means, areas such as goods receipt, quarantine pending examination, storage of released goods, non-conforming goods, returns, recalled goods and dispatch. 2. **One-way flow**: design sensible goods-flow routes so that, as far as possible, medicines move in one direction from receipt to dispatch, avoiding unnecessary backtracking and crossovers. 3. **Adequate space**: ensure that all areas have enough space for orderly storage and operations, avoiding excessive stacking or blocked passageways. 4. **Environmental controls**: areas requiring special storage conditions, such as refrigeration, protection from light or ventilation, should be specifically designed and equipped with suitable facilities. 5. **Security**: offices, rest areas and other non-operational areas should be separated from medicine storage areas. Storage areas for controlled medicines require additional security measures.

📘 Regulatory basis

Chapter 3, “Premises and Equipment”, of the Good Distribution Practice (GDP) for Medicinal Products sets out clear requirements for the design and layout of storage areas, emphasising the importance of functional segregation, preventing mix-ups and cross-contamination, and providing appropriate storage conditions.

📗 Drew Tang's recommendations

When planning the warehouse layout, draw a detailed floor plan showing all functional areas and the flow of goods. This plan will be an important document for demonstrating your design approach to the regulatory authorities. When designing the receiving and dispatch areas, consider providing a sheltered area to protect medicines from adverse weather during loading and unloading. The warehouse floors, walls and ceilings should be made of materials that are easy to clean.

📕 Risk notice

A warehouse with a disorganised layout and unclear functional zones is a major problem area in a GDP inspection. If released goods, non-conforming goods and returned goods are stored together, inspectors will immediately conclude that your system presents a serious risk of medicine mix-ups and incorrect dispatch. This could directly result in a failed inspection or a requirement for you to suspend operations immediately and carry out remedial work.

Q347 · 在对一个新的药品供应商进行首次资质审核时，应执行哪些关键步骤？独立链接

Initial qualification of new suppliers is the first safeguard for ensuring that your supply chain is lawful and compliant at source, and must be conducted with great care. Key steps include: 1. **Document review**: Ask the supplier for a complete set of qualification documents, including its business licence, medicines trading licence (such as a wholesale licence) and, where applicable, the manufacturer’s GMP certificate. Verify that these documents are authentic and valid. 2. **Questionnaire**: Send the supplier a detailed quality system questionnaire to understand its QMS, including its personnel, facilities, SOP system, temperature-control capabilities and recall procedures. 3. **Risk assessment**: Use the document review and questionnaire results to conduct an initial assessment of the supplier’s potential compliance risk. 4. **On-site audit (for high-risk suppliers)**: For critical, high-risk suppliers—for example, the sole supplier from which you plan to source a core product—an on-site audit is strongly recommended to verify in person that its operations match the documents. 5. **Approval and agreement**: Only after all review steps have been completed satisfactorily should the supplier be added to the “Approved Supplier List” and a formal quality agreement signed.

📘 Regulatory basis

Chapter 5, “Operations”, of the Good Distribution Practice (GDP) for Medicinal Products expressly provides that wholesalers must procure medicines from suppliers holding the relevant licences. You are responsible for verifying this through a formal qualification procedure.

📗 Drew Tang's recommendations

Establish a standardised new-supplier qualification SOP and checklist to ensure every assessment is thorough and consistent. Do not rely solely on documents supplied by the supplier; cross-check the authenticity of its licence using public government databases, such as the Department of Health website. Treat supplier qualification as an investment, not a cost. A sound start can prevent countless problems later.

📕 Risk notice

Purchasing medicines from a new supplier based solely on commercial negotiations, without adequate qualification checks, is extremely risky. You may unknowingly obtain medicines through an unlicensed or non-compliant channel, or even purchase counterfeit medicines. If discovered, you may face serious legal and regulatory penalties for failing to fulfil your due diligence responsibilities.

Q348 · 如何对一条新的药品运输路线进行风险评估？独立链接

Risk assessment of a new transport route is a key step in ensuring that medicines are adequately protected on a new, unvalidated route. The assessment should be systematic and documented: 1. **Define the route and products**: Specify the starting point, destination and key transit points, as well as the specific storage requirements of the medicines to be transported (such as room temperature or cold chain). 2. **Identify risk factors**: Brainstorm all risks that could affect medicine quality. These include transit time, climatic conditions in the regions along the route (extreme heat or cold), the likelihood of traffic delays, customs inspection procedures and duration, storage conditions at transit points, and security risks during transport. 3. **Assess risk levels**: For each identified risk, assess its probability of occurrence and the severity of its impact on medicine quality if it occurs. Combine the two to determine the level of each risk (high, medium or low). 4. **Establish control measures**: Develop specific control and mitigation measures for all medium- and high-level risks. For example, a validated passive cooler may be needed to address heat risk, while extra cool packs may be required in the packaging to mitigate delay risk. 5. **Validation and monitoring**: During the first commercial shipment or a simulated shipment, use temperature loggers to verify the effectiveness of the control measures.

📘 Regulatory basis

GDP requires transport processes to be designed and controlled on the basis of risk assessment. Although no specific assessment method is prescribed, using a structured risk assessment process is the best way to demonstrate that you have met this requirement.

📗 Drew Tang's recommendations

Develop a standardised template for transport-route risk assessments. Involve personnel from Quality, Logistics and Procurement in the assessment to gain a broader perspective. Remember to consider the “human factor”, such as whether staff at transit points have received relevant training. Retain the complete risk assessment report as the basis for your decision to select a particular transport arrangement.

📕 Risk notice

Sending medicines along a new, particularly long-distance international, transport route without conducting a risk assessment is like walking blindfolded into the unknown. You cannot anticipate or control the various incidents that may occur in transit. If a problem arises (such as a cold-chain failure), your lack of prior risk assessment and control planning may be considered serious negligence.

Q349 · 一份详尽的内部审核（自我检查）报告应包含哪些内容？独立链接

An internal audit report is a key document for recording audit findings and driving subsequent improvements; its quality directly affects the effectiveness of the audit. A detailed report should be clearly structured and specific. It should include at least the following sections: 1. **Basic information**: unique audit reference, audit date, scope (such as “storage operations” or “document system”), audit criteria (such as GDP guidance or company SOPs), auditor’s name and the department audited. 2. **Audit summary**: a brief overview of the audit and its main conclusions. 3. **Audit findings**: the core of the report. Clearly list each non-conformity (deficiency) separately. Describe the specific facts observed in detail (“where I was and what I saw”) and cite the specific legislative or SOP provision breached. 4. **Deficiency grading**: grade each deficiency according to its potential impact on product quality and regulatory compliance (for example, “critical”, “major” or “minor”). 5. **Recommendations (optional)**: the auditor may suggest improvements, but the audited department should determine the final corrective actions. 6. **Report distribution list and conclusion**.

📘 Regulatory basis

Self-inspections must be recorded under the Good Distribution Practice (GDP) for Medicinal Products, and the records should include all observations and proposed corrective measures. A structured report is the standard way of meeting this requirement.

📗 Drew Tang's recommendations

When describing audit findings, remain objective and fact-based, and avoid subjective or accusatory language. A good finding should enable anyone reading it to recreate the situation. For example, instead of writing ‘staff training was inadequate’, write ‘In the third-floor warehouse, staff member Zhang San did not follow the picking steps in SOP-W-005. When asked, he said that he was not familiar with the SOP.’ Such a description is compelling and effectively points to the root cause.

📕 Risk notice

An internal audit report that is vague and lacking in detail is ineffective. It does not provide clear input for subsequent CAPA, nor does it demonstrate to the regulator that a thorough, professional self-inspection was carried out. If the report always says “everything is fine”, or the issues it raises are trivial, the regulator may suspect that your internal audits are merely a formality.

Q350 · 对于不合格的、需要销毁的药品，应遵循怎样的最终处置（Final Disposition）程序？独立链接

Destroying non-conforming medicines is the final step in quality management and requires equally strict controls and records to ensure that the medicines do not accidentally re-enter the market. The disposal procedure should include: 1. **Formal decision**: The decision to destroy must be made by an authorised person in the Quality Department (such as the RP), who must sign a written destruction instruction. 2. **Segregation and records**: Medicines awaiting destruction should be kept in a secure, dedicated area clearly labelled ‘Awaiting Destruction’. Before destruction, check and record the name, batch number and quantity of the medicines one final time. 3. **Select a qualified destruction service provider**: Medicines must not be disposed of like ordinary rubbish. A specialist company qualified and authorised by the government to handle pharmaceutical waste must be engaged. You should verify its qualifications. 4. **Secure transport**: Transport the medicines awaiting destruction securely to the service provider’s premises and keep a record of the transport. 5. **Witnessing and certification**: If possible, send a staff member to witness the destruction on site. Whether or not it is witnessed, you must obtain a formal Certificate of Destruction from the service provider. This document is key legal evidence that the medicines have been disposed of lawfully. 6. **Update inventory**: Once destruction is confirmed, reduce the quantity of the medicines to zero in your inventory management system and archive all relevant records.

📘 Regulatory basis

GDP requires non-conforming goods to be segregated and properly handled. Although it does not set out the destruction process in detail, environmental laws and waste management regulations impose strict requirements on the disposal of medicines. You are responsible for ensuring that the destruction process complies with all relevant laws and regulations.

📗 Drew Tang's recommendations

Enter into a long-term contract with one or more qualified medicine destruction service providers. Set out the entire destruction process in your SOP and create a “medicine destruction record pack” containing all relevant documents, including destruction instructions, inventory records, transport documents and the final certificate of destruction. This creates a complete, traceable evidence trail.

📕 Risk notice

Carelessly discarding non-conforming medicines is extremely dangerous and irresponsible. It not only seriously breaches environmental regulations, but may also result in the medicines being found by others and misused or resold, creating a public safety risk. If you cannot provide lawful proof of destruction, you will be unable to demonstrate to the regulator that you have properly handled the non-conforming goods. This may be regarded as a loss of ultimate control over your supply chain.

Q351 · 作为持牌批发商，我们每天需要履行的核心合规义务有哪些？独立链接

As a licensed wholesale dealer, day-to-day compliance is the foundation for maintaining the validity of your licence. You must ensure that all procurement, storage, sale and distribution activities involving medicines strictly comply with Hong Kong law. Core obligations include: first, establishing and maintaining a robust Quality Management System (QMS) covering all operating procedures. Second, ensuring that all medicines are procured from qualified suppliers and keeping complete purchasing records. Third, storing medicines strictly in accordance with the label instructions, particularly those requiring specific temperature or humidity conditions, which must be monitored continuously and recorded. Fourth, keeping detailed sales and distribution records to ensure traceability; records must be retained for at least two years. Fifth, appointing one or more responsible persons to oversee day-to-day operations and ensuring all staff receive appropriate training and are familiar with their duties and relevant regulatory requirements.

📘 Regulatory basis

Under the Pharmacy and Poisons Ordinance (Cap. 138) and its subsidiary regulations, as well as the Code of Practice for Wholesale Dealers in Drugs, licensed wholesalers must establish and maintain an effective quality assurance system for their business activities to ensure the quality, safety and efficacy of medicines.

📗 Drew Tang's recommendations

We recommend that clients incorporate compliance requirements into everyday workflows rather than treating them as an additional burden. For example, electronic record systems can greatly improve efficiency and accuracy. Holding regular internal compliance review meetings and involving all staff can effectively raise compliance awareness across the team. Rengangyongsheng (Hong Kong) Limited can help you establish a tailored QMS to ensure that you meet regulatory requirements with ease.

📕 Risk notice

Failure to fulfil routine compliance obligations can have serious consequences, even when the lapse appears minor. If the Department of Health identifies a breach during an inspection, it may issue a warning letter requiring corrective action by a specified deadline; more serious cases may result in suspension or revocation of your licence, or even criminal prosecution. Do not take this lightly.

Q352 · 卫生署药物办公室进行例行视察时，通常会重点检查哪些方面？我们应该如何准备？独立链接

Routine inspections by the Department of Health are intended to ensure that licence holders continue to comply with the relevant legislation and codes of practice. Inspections are usually unannounced, although advance notice may also be given. The main areas checked include: 1. Premises and facilities: whether they meet the standards set at the time of licensing, particularly whether the warehouse environment for medicine storage meets the requirements. 2. Documents and records: the main focus of the inspection, including records of medicine purchases, sales and stock, as well as temperature monitoring and staff training records. 3. Operation of the Quality Management System: inspectors will sample-check whether your Standard Operating Procedures (SOPs) are being implemented effectively. 4. Personnel qualifications and responsibilities: ensuring that personnel in key roles have the relevant qualifications and clearly understand their responsibilities. To prepare, ensure all documents and records are well organised and readily accessible, and provide staff with regular training and mock inspection exercises so they can remain composed and answer questions accurately during an inspection.

📘 Regulatory basis

The Pharmacy and Poisons Ordinance (Cap. 138) authorises the Director of Health or an authorised person to enter licensed premises at any reasonable time to inspect whether the licence holder is complying with the requirements of the Ordinance.

📗 Drew Tang's recommendations

We view an inspection as a “free health check” of the company’s compliance system. Rather than responding passively, prepare proactively. We recommend that clients establish an “inspection preparation folder” containing copies or an index of all documents that may be reviewed. During the inspection, assign a senior employee familiar with the situation to accompany the inspectors throughout and answer questions clearly and accurately, making a positive impression of professionalism and rigour.

📕 Risk notice

Providing false or misleading information during an inspection is a serious offence. If incomplete records or signs of falsification are discovered, you may face severe penalties. In addition, obstructing inspectors in the performance of their duties may constitute a criminal offence. Cooperate with the inspection openly and honestly.

Q353 · 关于药品的进出记录，卫生署要求的具体标准是什么？需要保存多久？独立链接

Records of medicine receipts and issues are central to the medicine traceability system and a key focus of regulatory inspections. Under the requirements, records of all receipts and issues of Part I poisons and dangerous drugs in Schedules 1 and 3 must be detailed and accurate. The specific standards are as follows: for purchases (receipts), records must include the purchase date, medicine name, dosage form, strength, quantity, and supplier’s name and address. For sales (issues), records must include the sale date, medicine name, dosage form, strength, quantity, and purchaser’s name and address. Each transaction should be supported by a corresponding invoice or document. All records must be maintained legibly and indelibly, whether in paper ledgers or an electronic system. They must be entered as soon as possible after each transaction and retained for at least two years from the date of the last entry.

📘 Regulatory basis

The Pharmacy and Poisons Regulations (Cap. 138A) set out clear requirements for the sale of poisons and record-keeping. Section 28 specifies in detail the information that must be included in a Poisons Register. The Code of Practice for Wholesale Dealers in Poisons also provides detailed guidance on this.

📗 Drew Tang's recommendations

We strongly recommend that clients use an electronic inventory management system that complies with Good Distribution Practice (GDP). This helps ensure the accuracy and integrity of records and enables reports to be generated quickly when needed, greatly simplifying traceability and stocktaking. When selecting a system, ensure that it has access controls and tamper-proof functions to meet regulatory requirements. Rengangyongsheng (Hong Kong) Limited can recommend a suitable system and help you implement it.

📕 Risk notice

Inaccurate or incomplete receipt and dispatch records are among the most common breaches by wholesalers. This not only affects pharmaceutical traceability, but may also prevent you from establishing the extent of your responsibility if a pharmaceutical safety issue arises. If seriously inaccurate records are identified during an inspection, this may be grounds for revoking the licence.

Q354 · 如果发现或收到关于药品不良反应的报告，我们应遵循怎样的呈报程序？独立链接

Monitoring and reporting adverse drug reactions (ADRs) is an important duty of licence holders in safeguarding public medicine safety. If, as a licensed wholesaler or manufacturer, you learn through any channel (such as healthcare professionals, patients or sales representatives) of information about a serious adverse reaction to a medicine you supply, you must initiate the reporting procedure. This generally involves: first, conducting an initial assessment immediately and collecting as much detail as possible, including information about the patient, medication history, and the nature and course of the adverse reaction. Next, completing the ADR report form provided by the Drug Office, Department of Health, under the Drug Safety Monitoring Programme. Finally, reporting it to the Department of Health within the prescribed time limit according to the seriousness of the reaction (unexpected and serious ADRs are generally required to be reported within 15 calendar days).

📘 Regulatory basis

Although Hong Kong law does not require all ADRs to be reported, the Codes of Practice for Pharmaceutical Wholesalers and Pharmaceutical Manufacturers both expressly state that licence holders are responsible for establishing a pharmacovigilance system and reporting serious or unexpected adverse reactions identified to the Department of Health.

📗 Drew Tang's recommendations

Establishing an internal pharmacovigilance Standard Operating Procedure (SOP) is essential. The SOP should identify the personnel responsible for handling ADR reports, information-collection templates, assessment criteria, and the specific procedures and timelines for reporting to the Drug Office, Department of Health. Regular training for sales and marketing staff on identifying and initially handling ADR information is key to ensuring it reaches the pharmacovigilance department promptly.

📕 Risk notice

Late, incomplete or concealed reporting of serious adverse drug reactions will not only damage the company’s reputation but may also pose a threat to public health. If the Department of Health learns of the matter through other channels and the licence holder has not reported it promptly, serious questions may be raised about the licence holder’s integrity and professional competence, potentially leading to further in-depth investigation and regulatory action.

Q355 · 在什么情况下需要启动药品召回？具体的流程是怎样的？独立链接

A medicine recall is an urgent measure taken to protect public health when a quality, safety or efficacy problem is found in a medicine already on the market. Circumstances requiring a recall include contamination, incorrect labelling, packaging defects, incorrect active ingredient content and failed stability tests. Once a recall is deemed necessary, the licensed manufacturer or wholesaler must immediately notify the Department of Health and initiate its internal recall procedure. The general process is: 1. Risk assessment: determine the seriousness of the issue and its potential scope, and define the recall level (for example, recall to the doctor/pharmacy level or to the consumer level). 2. Notification and communication: submit a detailed recall plan to the Department of Health and promptly notify all affected downstream customers, such as other wholesalers, hospitals and pharmacies. 3. Recall execution: arrange logistics to retrieve all affected batches and segregate them in storage. 4. Investigation and reporting: thoroughly investigate the root cause, take corrective and preventive action (CAPA), and submit the final recall and investigation reports to the Department of Health.

📘 Regulatory basis

Both the Code of Practice for Licensed Wholesale Dealers and the Code of Practice for Licensed Manufacturers require licensees to establish effective medicine recall procedures. The Department of Health has also issued Guidance Notes on the Recall of Pharmaceutical Products, providing the industry with detailed operational guidance.

📗 Drew Tang's recommendations

The key to an effective recall procedure is to act quickly and accurately. We recommend that clients establish a recall response team in advance, with the responsibilities of each member clearly defined. Regular mock recalls can test and improve your recall process, ensuring it can be carried out quickly and efficiently in a real situation. Accurate and complete pharmaceutical product distribution records are essential for a targeted recall.

📕 Risk notice

Improper recall handling can severely undermine market and consumer confidence in your products and your company as a whole. Delaying the start of a recall or failing to notify downstream customers effectively may result in problematic pharmaceutical products continuing to be used, causing harm to health and leading to legal proceedings and substantial compensation claims. The Department of Health also closely monitors recalls; any failure may result in additional regulatory penalties.

Q356 · 什么是年度自我视察（Self-Inspection）？它和卫生署的视察有何不同？独立链接

Annual self-inspection is an important part of a licence holder’s Quality Management System (QMS) and is a proactive internal compliance audit. Its purpose is to systematically and critically review all company activities related to medicine quality, assess ongoing compliance with Good Distribution Practice (GDP) or Good Manufacturing Practice (GMP) requirements, and identify areas for improvement. It differs from a Department of Health inspection in three main respects: first, in nature—the former is an internal, proactive activity, while the latter is an external regulatory activity; second, in purpose—self-inspection aims at self-improvement and continual improvement, while a Department of Health inspection aims at enforcement and oversight; and third, in frequency and scope, which can be more flexible, allowing the company to conduct more frequent internal audits of high-risk areas based on risk assessment.

📘 Regulatory basis

Both the Code of Practice for Licensed Wholesale Dealers and the Code of Practice for Licensed Manufacturers expressly require licensees to conduct self-inspections regularly to monitor the implementation and effectiveness of their quality assurance systems, and to retain inspection records.

📗 Drew Tang's recommendations

Do not treat self-inspection as a box-ticking exercise. A successful self-inspection should be no less thorough or wide-ranging than an official inspection. We recommend setting up an independent audit team comprising staff from different departments and conducting a systematic review using a pre-prepared checklist. After the inspection, issue a formal report detailing the findings, root-cause analysis and recommended corrective and preventive action (CAPA), assign an owner and completion deadline, and follow up to complete the full PDCA (Plan-Do-Check-Act) cycle.

📕 Risk notice

If self-inspections are merely a formality and do not genuinely identify and resolve problems, those problems will still be exposed during a Department of Health inspection. The regulator will then question not only the problems themselves, but also the effectiveness of your Quality Management System. Having records showing that self-inspections were conducted but failed to identify obvious problems is worse than not conducting inspections at all.

Q357 · 对于处理药品的员工，我们需要提供哪些必要的培训？培训记录需要多详细？独立链接

Staff are the first line of defence in ensuring medicine quality and compliant operations, so ongoing, effective training is essential. Necessary training should include: 1. Induction training covering the company's quality policy, basic GDP/GMP concepts, personal hygiene requirements, and employees' own roles and relevant Standard Operating Procedures (SOPs). 2. Role-specific skills training for particular tasks such as receipt, acceptance, storage, picking, packing and transport. 3. Medicine knowledge training, particularly on the characteristics, storage conditions and expiry-date management of the medicines handled. 4. Compliance and regulatory training to refresh staff regularly on relevant legislation, including the Pharmacy and Poisons Ordinance. Training records must be comprehensive and include the date, subject, outline of content, trainer, employee signatures and an assessment of training effectiveness. These records are key evidence to the regulator that you have fulfilled your training obligations.

📘 Regulatory basis

Both the Code of Practice for Licensed Wholesale Dealers and the Code of Practice for Licensed Manufacturers emphasise that all staff engaged in activities affecting medicine quality should receive initial and ongoing training appropriate to their duties, and that relevant training records should be retained.

📗 Drew Tang's recommendations

Training should not be a one-off event. We recommend that clients establish an annual training plan and adjust its content as needed in response to regulatory updates, the introduction of new products or issues identified during internal audits. A variety of methods, such as classroom teaching, on-the-job coaching, case studies and even prize quizzes, can improve staff engagement and learning outcomes. Linking training completion to staff performance appraisals can also be an effective incentive.

📕 Risk notice

Insufficient training or incomplete training records are common inspection deficiencies. If an employee causes a medicine quality issue because they do not understand the correct procedures, the company will bear full responsibility. In the event of a serious incident, inadequate training records will place the company at a considerable disadvantage in legal proceedings.

Q358 · 我们是一家持牌批发商，如果需要从海外进口或出口药品，需要申请额外的许可吗？独立链接

Yes, holding a Wholesale Dealer Licence does not automatically grant the right to import or export medicines. The import and export of medicines are strictly controlled under Hong Kong law. You must apply to the Department of Health for an import or export licence for each consignment of pharmaceutical products or substances registered in Hong Kong, whether importing or exporting. You will need to provide detailed information about the goods, including the medicine name, ingredients, quantity and manufacturer details, as well as relevant supporting documents from the place of origin or destination country. The Department of Health will assess each application to ensure that the import or export activities comply with local regulations and international standards. Unregistered medicines are in principle not permitted to be imported or exported unless a special exemption is granted (for example, for clinical trials or a specific patient).

📘 Regulatory basis

Under the Import and Export Ordinance (Cap. 60) and the Import and Export (General) Regulations made under it, pharmaceutical products and substances are controlled articles. Their import or export requires a valid licence issued by the Department of Health under the authority of the Director-General of Trade and Industry.

📗 Drew Tang's recommendations

We recommend that clients fully understand and plan the import and export licence application process before signing contracts with overseas suppliers or customers. As approval takes time, prepare all required documents in advance and allow sufficient time for the application to avoid delaying shipments. For frequent, small-volume imports and exports, you can discuss with the Department of Health whether a simplified application procedure is available. Rengangyongsheng (Hong Kong) Limited has extensive experience handling import and export licence applications and can manage the paperwork to help ensure a smooth process.

📕 Risk notice

Any unauthorised import or export of medicines constitutes smuggling and is a serious criminal offence. Upon conviction, the company and the Person-in-Charge may face substantial fines and imprisonment, and the company’s Wholesale Dealer Licence is also highly likely to be revoked. Do not break the law to save time or costs; the consequences could be disastrous.

Q359 · 在药品库存管理方面，除了保证先进先出，还有哪些关键的合规要点？独立链接

Effective inventory management is central to ensuring medicine quality and safety. In addition to strictly applying the “first-expired-first-out” (FEFO) principle (that is, dispatching items with the earliest expiry date first, which is more accurate than FIFO), the following key compliance points apply: 1. Clear zoning: the warehouse must have clearly designated areas for quarantined goods pending examination, released goods, non-conforming goods, returned goods and recalled goods, with clear signs to distinguish them and prevent mix-ups and cross-contamination. 2. Environmental monitoring: medicines with specific temperature and humidity requirements must be monitored and recorded continuously, 24 hours a day, using calibrated equipment. There must be an emergency plan for environmental excursions, and actions taken must be documented. 3. Regular stocktakes: stock must be counted regularly, and physical inventory reconciled against stock records. Any discrepancies must be investigated and documented. 4. Expiry-date management: establish an expiry-date alert system and closely monitor medicines approaching their expiry date to prevent expired medicines from being dispatched accidentally. 5. Security: take appropriate security measures to prevent unauthorised access to storage areas and prevent medicines from being stolen or tampered with.

📘 Regulatory basis

The Code of Practice for Licensed Wholesale Dealers sets out detailed requirements for the storage, stock control and distribution of medicines, requiring licensees to take all necessary measures to maintain medicine quality throughout the supply chain.

📗 Drew Tang's recommendations

We recommend that clients treat stock management as a dynamic process. An electronic inventory system using barcodes or RFID can greatly improve the accuracy of FEFO implementation, stocktaking efficiency and medicines tracking. For high-value or controlled medicines, consider higher-level security measures, such as a separate locked storage area and video surveillance. Regular inventory analysis can also help optimise procurement planning and reduce tied-up capital and losses from expired products.

📕 Risk notice

Disorganised inventory management creates conditions in which medicine quality problems can arise. Accidentally supplying non-conforming or expired goods to customers can lead not only to complaints and commercial losses, but also to medicine safety incidents, regulatory penalties and legal liability. Medicines deteriorating because of improper storage conditions is likewise a serious breach.

Q360 · 作为“获授权毒药销售商”（药房），我们销售第一部毒药时，对处方有什么具体要求？独立链接

As an authorised pharmacy, you must dispense Part I poisons strictly in accordance with a prescription issued by a qualified registered medical practitioner, dentist or veterinary surgeon. The prescription must be lawful and complete. Specific requirements include: 1. It must be written in indelible form. 2. It must include the date of issue, the patient's full name and address, and the prescribing practitioner's name, address and signature. 3. It must clearly state the name of the medicine to be dispensed, dosage instructions and total quantity to be supplied. 4. For certain strictly controlled dangerous drugs, the patient's identity card number may also be required on the prescription. Before dispensing, the pharmacist is responsible for verifying the prescription's authenticity and reasonableness. If there is any doubt, such as an unusual dosage or suspected forgery, the pharmacist must contact the prescriber for confirmation before dispensing.

📘 Regulatory basis

Sections 21 to 27 of the Pharmacy and Poisons Regulations (Cap. 138A) set out in detail the conditions for the sale of Part I poisons, including requirements for the form and content of prescriptions and dispensing records.

📗 Drew Tang's recommendations

We recommend that pharmacies establish a standard prescription review process. Exercise particular caution with a doctor’s signature you have not seen before or an unfamiliar prescription format. Keeping specimen signatures of locally registered doctors (where available) or checking through the Hospital Authority’s electronic Health Record Sharing System (eHRSS) are good practices. After dispensing, stamp the prescription with “Dispensed”, the pharmacy name and address, and the dispensing date, and retain it for at least two years as required.

📕 Risk notice

Selling Part I poisons without a prescription or on the basis of an unlawful prescription is a very serious offence. This may expose the pharmacy and the pharmacist on duty not only to criminal prosecution, fines and even imprisonment, but also to disciplinary action by the Pharmacy and Poisons Board (PPB), ultimately resulting in the pharmacy licence being revoked and the pharmacist's registration being cancelled. Never breach the rules because of a customer's request or for convenience.

Hong Kong Drug Licence FAQs

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang